Picture of Prostatype Genomics AB logo

PROGEN Prostatype Genomics AB Share Price

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m+33.46%
3m-14.65%
6m-60.71%
1yr-74.4%
Volume Change (%)
10d/3m+73.55%
Price vs... (%)
52w High-78.46%
50d MA+2.11%
200d MA-49.43%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-93.49%
Return on Equity-98.33%
Operating Margin-8290.72%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Prostatype Genomics AB EPS forecast chart

Profile Summary

Prostatype Genomics AB is a Sweden-based company developing gene tests. The Company manufactures, markets and sells the prognostic gene test Prostatype. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.

Directors

    Last Annual
    December 31st, 2021
    Last Interim
    June 30th, 2022
    Incorporated
    January 1st, 1970
    Public Since
    January 1st, 1970
    Sector
    Healthcare Providers & Services
    Industry
    Healthcare
    Exchange
    se flag iconOMX Nordic Exchange Stockholm
    Shares in Issue
    15,103,602

    PROGEN Share Price Performance

    Upcoming Events for PROGEN

    Similar to PROGEN

    Picture of Ambea AB (publ) logo

    Ambea AB (publ)

    se flag iconOMX Nordic Exchange Stockholm

    Picture of Attendo AB (publ) logo

    Attendo AB (publ)

    se flag iconOMX Nordic Exchange Stockholm

    Picture of Bonzun AB (publ ) logo

    Bonzun AB (publ )

    se flag iconOMX Nordic Exchange Stockholm

    Picture of Bonzun AB (publ ) logo

    Bonzun AB (publ )

    se flag iconOMX Nordic Exchange Stockholm

    Picture of Humana AB logo

    Humana AB

    se flag iconOMX Nordic Exchange Stockholm

    FAQ

    Or unlock with your email

    Or unlock with your email